Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Year : 2020  |  Volume : 41  |  Issue : 1  |  Page : 54-56

Trastuzumab: A milestone in human epidermal growth factor receptor 2-positive breast cancer

Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India

Correspondence Address:
Dr. Manikandan Dhanushkodi
Department of Medical Oncology, Cancer Institute (WIA), 38, Sardar Patel Road, Chennai . 600 036, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijmpo.ijmpo_252_19

Rights and Permissions

Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 25% of breast cancers. Patients with HER2-positive breast cancer have aggressive disease and inferior survival. HER2 overexpression is assessed by immunohistochemistry or fluorescent in situ hybridization-based methods. Trastuzumab has shown to improve survival in HER2-positive breast cancer. It is recommended in patients with >T1c for 1-year duration in adjuvant setting, preferably given concurrently with taxane.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded42    
    Comments [Add]    

Recommend this journal